{"attachments":[{"id":"46917000-5646-4be9-8630-7773e34f6f88","project_id":"7ce4c2a8-933d-4f7a-b302-372df511b0b3","url":"https://www.amed.go.jp/content/000149486.pdf","filename":"Strengthening Program for Pharmaceutical Startup Ecosystem（September 2025）","mime":"","bytes":0,"key_points":"","extract_status":"pending","downloaded_at":null,"created_at":"2026-08-15T13:00:46.290412+02:00"},{"id":"eac8ef19-8322-412b-86bb-72b883c49d34","project_id":"7ce4c2a8-933d-4f7a-b302-372df511b0b3","url":"https://www.amed.go.jp/content/000149488.pdf","filename":"創薬ベンチャーエコシステム強化事業（2025年9月）","mime":"","bytes":0,"key_points":"","extract_status":"pending","downloaded_at":null,"created_at":"2026-08-15T13:00:46.293236+02:00"}],"project":{"id":"7ce4c2a8-933d-4f7a-b302-372df511b0b3","title":"Strengthening Program for Pharmaceutical Startup Ecosystem","title_normalized":"strengtheningprogramforpharmaceuticalstartupecosystem","sponsor":"Japan Agency for Medical Research and Development","agency":"Japan Agency for Medical Research and Development","kind":"subsidy","taxonomy":["生醫健康"],"region":"日本","deadline":null,"starts_at":null,"announced_at":null,"budget":"","eligibility":"1. 製藥創業公司（Pharmaceutical Startups）進行非臨床、第1期、第2期或探索性臨床試驗階段的開發與商業化。\\n2. 須由登錄的風險投資公司（Registered VC）投資超過總補助費用的三分之一。\\n3. 日本境內註冊的藥廠創業公司，以及為海外募資或商業化而設立的外國公司日本子公司均符合資格。","summary":"此計畫旨在透過登錄風險投資公司提供的實質投資，支持日本藥創業公司在非臨床至探索性臨床試驗階段的藥物開發與商業化，特別擴大至傳染病以外的藥物研發領域，並鼓勵國際市場佈局，以提升日本藥創業生態系統的資金基礎與全球競爭力。","url":"https://www.amed.go.jp/en/program/list/19/02/005.html","url_status":"ok","url_checked_at":"2026-09-05T17:21:52.3584+02:00","source_id":null,"snapshot_id":"068b2f6c-130b-411f-908f-e03eac3481b4","spec_id":null,"lifecycle":"open","first_seen_at":"2026-08-15T13:00:46.255486+02:00","last_verified_at":"2026-08-15T13:00:46.269213+02:00","created_at":"2026-08-15T13:00:46.255991+02:00","updated_at":"2026-09-05T17:21:52.359687+02:00"}}